Myriad’s shares rose 4.5% after earnings, with investors likely responding to a modestly higher 2026 revenue outlook, sequential improvement in average revenue per test and the $210 million agreement to sell its Prenatal Health business. The quarter still showed pressure in Prenatal Health volumes and year-over-year declines in Cancer Care average revenue per test.
Shares dropped 16.8% following the quarter, reflecting investor disappointment with margin compression and cautious outlook despite steady revenue growth and reaffirmed guidance.